A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice

Translational Stroke Research

Volumn 1, Issue 3, 2010, Pages 170-177

  Mandava, Pitchaiah ^a   Dalmeida, William ^a   Anderson, Jane A ^a   Thiagarajan, Perumal ^a   Fabian, Roderic H ^a   Weir, Raymond U ^b   Kent, Thomas A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Abciximab; Glycoprotein IIB IIIA receptor antagonists; GP IIB IIIA inhibitors; Ischemic stroke; Matching algorithm; Platelet aggregation units; Platelet function inhibition

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; GLUCOSE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; PLACEBO;

ADULT; AGED; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BASILAR ARTERY; BLOOD FLOW; BLOOD VESSEL OCCLUSION; BRAIN CIRCULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; FEMALE; GLUCOSE BRAIN LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

EID: 77954957785     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-010-0026-4     Document Type: Article

References (55)

1. Lo E, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke. 2004; 35: 354-6.
2. Mandava P, Kent TA. Intra-arterial therapies for acute ischemic stroke. Neurology. 2007; 68: 2132-9.
3. Mandava P, Suarez JI, Kent TA. Intravenous rt-PA versus endovascular therapy for acute ischemic stroke. Curr Atheroscl Rep. 2008; 40: 1803-10.
4. Mandava P, Kent TA. A method to determine stroke trial success using multidimensional pooled control functions. Stroke. 2009; 40: 1803-10.
5. Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol. 2003; 42: 1178-85.
6. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percuataneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006; 367: 569-78.
7. Adams HP, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al. Emergency administration of Abciximab for treatment of patients with acute ischemic stroke: results of an International Phase III Trial: Abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke. 2008; 39: 87-99.
8. Mandava P, Thiagarajan P, Kent TA. Glycoprotein IIb/IIIa antagonists in acute Ischaemic stroke. Current status and future directions. Drugs. 2008; 68: 1019-28.
9. Choudhri TF, Hoh BL, Zerwes H-G, Prestigiacomo CJ, Kim SC, Connolly Jr ES, et al. Reduced microvascular Thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998; 102: 1301-10.
10. 3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke. 2000; 31: 1402-10.
11. Ding G, Jiang Q, Zhang L, Zhang ZG, Li L, Knight RA, et al. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIB/IIIa inhibitor. JCBF. 2005; 25: 87-97.
12. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation. 1989; 80: 1766-74.
13. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007; 115: 2323-30.
14. Samra SK, Harrison RL, Bee DE, Valero V. A study of aspirin induced changes in bleeding time, platelet aggregation, and Sonoclot coagulation analysis in humans. Ann Clin Lab Sci. 1991; 21: 315-27.
15. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005; 36: 880-90.
16. Theroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefit. Am Heart J. 1997; 134: S62-70.
17. The Epic Investigators. Use of monoclonal antibody directed against the platelet glycoprotein iib/iiia receptor in high risk coronary angioplasty. N Eng J Med. 1994; 330: 956-61.
18. The Impact II investigators. Randomized placebo controlled trial of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimize platelet aggregation and coronary thrombosis-II. Lancet. 1997; 349: 1422-8.
19. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7e3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation. 1997; 95: 1755-9.
20. Mandava P, Kalkonde YV, Rochat R, Kent TA. A matching algorithm to address imbalances in study populations. Application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator Acute Stroke Trial. Stroke. 2010; 41: 765-70.
21. Cheung RT, Ho DS. Fatal hemorrhagic transformation of acute cerebral infarction after the use of abciximab. Stroke. 2000; 31: 2526-7.
22. Lee KY, Heo JH, Lee SI, Yoon PH. Rescue treatment with abciximab in acute ischemic stroke. Neurology. 2001; 56: 1585-7.
23. Mandava P, Lick SD, Rahman MA, Langsjoen H, Reddy KV, Nelson J, et al. Initial safety experience of abciximab and heparin for acute ischemic stroke. Cerebrovasc Dis. 2005; 19: 276-8.
24. Mandava P, Kent TA. Reversal of dense signs predicts recovery in acute ischemic stroke. Stroke. 2005; 36: 2490-2.
25. Steinhubl SR, Kottke-Marchant K, Moliterno DJ. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation. 1999; 100: 1977-82.
26. Steinhubl SR, Talley D, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) Multicenter Study. Circulation. 2001; 103: 2572-8.
27. Steinhubl SR. Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonist. Coron Artery Dis. 2003; 14: 381-6.
28. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333: 1581-7.
29. Bergstralh EJ, Kosanke JL. Computerized matching of cases to controls. Technical report 56. Available at http://mayoresearch. mayo. edu/mayo/research/biostat/upload/56. pdf. Accessed 2 April 2010.
30. NIST/SEMATECH e-Handbook of Statistical Methods. Available at www. itl. nist. gov/div898/handbook/ Chapters 1& 7. Accessed 2 April 2010.
31. Dachs RJ, Burton H, Joslin J. A user's guide to the NINDS rt-PA stroke trial database. PLoS Med. 2008; 5: e113.
32. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274: 1017-25.
33. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352: 1245-51.
34. Ali M, Bath PM, Curram J, Davis SM, Diener HC, Donnan GA, et al. The virtual international stroke trials archive. Stroke. 2007; 38: 1905-10.
35. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in responses to recombinant tissue plasminogen activator in acute ischemic stroke. A pooled analysis of randomized clinical trials. Stroke. 2005; 36: 62-5.
36. Uchino K, Billheimer D, Cramer SC. Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke. 2001; 32: 909-16.
37. Weimar C, König IR, Kraywinkel K, Ziegler A, Diener HC, German Stroke Study Collaboration. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke. 2004; 35: 158-62.
38. Bruno A, Williams LS, Kent TA. How important is hyperglycemia during acute brain infarction? Neurologist. 2004; 10: 195-200.
39. Matlab. The language of technical computing. The Mathworks Inc. Boston, MA. Pp11. 18-11. 37.
40. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Intervent. 2009; 2: 222-9.
41. Wong PC, Crain EJ, Watson CA, Jiang X, Hua J, Bostwick JS, et al. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits. J Cardiovasc Pharmacol. 2007; 49: 316-24.
42. 2T receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999; 42: 213-20.
43. Lampl Y, Jivin JA, Fisher M, Lew R, Welin L, Dahlof B, et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke. 2007; 38: 1843-9.
44. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke. The CLEAR Stroke Trial. Stroke. 2008; 39: 3268-76.
45. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999; 282: 2003-11.
46. Hacke W, Kaste M, Bluhmki E, Brozman M, Davolos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008; 359: 1317-29.
47. Grotta JC. National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. The NINDS Stroke Study Group response. J Stroke Cerebrovasc Dis. 2002; 11: 121-4.
48. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, et al. Findings from the reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial. Stroke. 2004; 35: 2418-24.
49. Ribo M, Molina C, Montaner J, Rubiera M, Delgado-Mederos R, Arenillas JF, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke. 2005; 36: 1705-9.
50. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. JCBF. 2007; 27: 435-51.
51. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke. 2000; 31: 601-9.
52. Phillipps J, Thomalla G, Glahn J, Schwarze M, Röther J. Treatment of progressive stroke with tirofiban-experience in 35 patients. Cerebrovasc Dis. 2009; 28: 435-8.
53. Martin-Schild S, Shaltoni H, Abraham AT, Barreto AD, Hallevi H, Gonzales NR, et al. Safety of eptifibatide for subcortical stroke progression. Cerebrovasc Dis. 2009; 28: 595-600.
54. Torgano G, Zecca B, Monzani V, Maestroni A, Rossi P, Cazzaniga M, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. Cerebrovasc Dis. 2010; 29: 275-81.
55. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008; 112: 3011-25.